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To explore mechanisms underlying triglyceride (TG) accumulation in livers of chow-fed apo
E-deficient mice (Kuipers, F., J.M. van Ree, M.H. Hofker, H. Wolters, G. In't Veld, R.J. Vonk,
H.M.G. Princen, and L.M. Havekes. 1996. Hepatology. 24:241-247), we investigated the
effects of apo E deficiency on secretion of VLDL-associated TG (a) in vivo in mice, (b) in
isolated perfused mouse livers, and (c) in cultured mouse hepatocytes. (a) Hepatic VLDL-
TG production rate in vivo, determined after Triton WR1339 injection, was reduced by 46%
in apo E-deficient mice compared with controls. To eliminate the possibility that impaired
VLDL secretion is caused by aspecific changes in hepatic function due to
hypercholesterolemia, VLDL-TG production rates were also measured in apo E-deficient
mice after transplantation of wild-type mouse bone marrow. Bone marrow- transplanted apo
E-deficient mice, which do not express apo E in hepatocytes, showed normalized plasma
cholesterol levels, but VLDL-TG production was reduced by 59%. (b) VLDL-TG production
by isolated perfused livers from apo E-deficient mice was 50% lower than production by
livers from control mice. Lipid composition of nascent VLDL particles isolated from the
perfusate was similar for both groups. (c) Mass VLDL-TG secretion by cultured apo E-
deficient hepatocytes was reduced by 23% compared with control values in serum-free
medium, and by 61% in the presence of oleate in medium (0. 75 mM) […]
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To explore mechanisms underlying triglyceride (TG) ac-
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24:241–247), we investigated the effects of apo






















) Hepatic VLDL-TG production
rate in vivo, determined after Triton WR1339 injection, was
reduced by 46% in apo E–deficient mice compared with
controls. To eliminate the possibility that impaired VLDL
secretion is caused by aspecific changes in hepatic function
due to hypercholesterolemia, VLDL-TG production rates
were also measured in apo E–deficient mice after transplan-
tation of wild-type mouse bone marrow. Bone marrow–
transplanted apo E–deficient mice, which do not express
apo E in hepatocytes, showed normalized plasma choles-





) VLDL-TG production by isolated perfused livers from
apo E–deficient mice was 50% lower than production by liv-
ers from control mice. Lipid composition of nascent VLDL





) Mass VLDL-TG secretion by cultured apo E–defi-
cient hepatocytes was reduced by 23% compared with control
values in serum-free medium, and by 61% in the presence of
oleate in medium (0.75 mM) to stimulate lipogenesis. Elec-
tron microscopic evaluation revealed a smaller average size
for VLDL particles produced by apo E–deficient cells com-
pared with control cells in the presence of oleate (38 and 49
nm, respectively). In short-term labeling studies, apo E–defi-















E–deficient cells was reduced by 60 and 73% in the absence
and presence of oleate, respectively. We conclude that apo
E, in addition to its role in lipoprotein clearance, has a phys-

































-rich chylomicrons and VLDL. apo E
functions as a ligand in the receptor-mediated uptake of these
lipoproteins by the liver (1) and may modulate their lipopro-
tein lipase–mediated processing (2, 3). It has also been sug-
gested that apo E plays a role in the secretion–recapture pro-
cess (4, 5). In this process, internalization of circulating
lipoproteins is facilitated through binding of the particles to
heparan sulfate proteoglycans and subsequent enrichment
with apo E in the hepatic sinusoidal space of Disse. Further-
more, recent in vitro studies have indicated that apo E may
serve a function in intracellular metabolism and distribution of
endocytosed lipids in macrophages and hepatoma cells (6, 7).
The generation of apo E–deficient mice has established di-
rectly the importance of apo E in control of plasma cholesterol
levels (8, 9). apo E–deficient mice show markedly elevated
plasma cholesterol levels when fed a normal chow diet, due to
accumulation of VLDL/LDL-sized particles in their circu-
lation (10–12). These particles contain predominantly apo
B48 and are relatively enriched in cholesterol and cholesterol
ester and depleted in TG (10–12). As recently reviewed by
Plump and Breslow (8), these particles are mainly remnants of
intestinal chylomicrons.
Data in the literature suggest that apo E may also have a
function in the assembly and/or secretion of VLDL by the
liver. Studies by Strobl et al. (13) showed that stimulation of
hepatic VLDL production in rats by feeding them sucrose-rich
diets enhances apo E synthesis and secretion by promoting
transcription of the apo E gene. Hamilton et al. (14) demon-
strated that apo E is present in nascent VLDL particles within
putatively forming Golgi secretory vesicles of rat hepatocytes.
Studies by Fazio et al. (15) showed that most of the apo E se-
creted by human hepatoma cells (HepG2) becomes associated
with large TG-containing lipoproteins when lipogenesis and
TG secretion are stimulated, whereas the total amount of apo
E synthesized and secreted is not affected. More recently,
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Fazio and Yao (16) reported that the association between apo
E and TG-rich lipoproteins in HepG2 and rat hepatoma cells
(McA-RH7777) takes place intracellularly rather than extra-
cellularly, after their secretion into the medium. Finally, recent
studies by our group demonstrated that apo E–deficient mice
accumulate large amounts of TG in their livers (17). There-
fore, altogether, scattered evidence is available to suggest that
apo E has a function in VLDL assembly and/or secretion.
In this paper, we investigated the effects of apo E defi-
ciency on VLDL-TG synthesis and secretion in vivo as well as
in vitro, using apo E–deficient mice, perfused apo E–deficient
mouse livers, and isolated apo E–deficient hepatocytes. These
studies demonstrate unequivocally that VLDL-TG production
is severely impaired in the absence of apo E, whereas TG syn-
thesis in apo E–deficient hepatocytes is not affected. In addi-
tion, impaired VLDL-TG production is also observed in apo
E–deficient mice in which plasma cholesterol levels have been
normalized by transplantation of wild-type bone marrow.
These data lead us to conclude that apo E has a modulating
role in the VLDL secretion cascade, representing a novel






apo E–deficient mice were generated as described previ-
ously (12). apo E–deficient and control (C57BL/6J) mice were
housed in a light- and temperature-controlled environment and had
free access to water and food.
To induce bone marrow aplasia, apo E–deficient and control mice
(age 5–6 wk) were exposed to a single dose of 13 Gy (0.28 Gy/min,
200 kV, 4 mA) x-ray total body irradiation using an Andrex Smart
225 (Andrex Radiation Products A/S, Copenhagen, Denmark) with a
4-mm aluminum filter, 1 d before transplantation. Bone marrow cell
suspensions were isolated by flushing the femurs and tibias from con-
trol mice with PBS. Single-cell suspensions were prepared by passing




m nylon gauze. Irradiated apo E–deficient








 bone marrow cells by intra-
venous injection into the tail vein. Mice used for bone marrow trans-
plantation experiments were housed in sterilized filter-top cages and
fed sterilized chow (SRM-A; Hope Farms BV, Woerden, The Neth-
erlands) containing 5.7% fat (wt/wt). Drinking water was supplied
with antibiotics (83 mg/liter ciprofloxacin and 67 mg/liter polymyxin
B sulphate) and 6.5 g/liter glucose.
For liver perfusion studies, female apo E–deficient and control
mice were used that were fed a low fat/low cholesterol (LFC) semi-
synthetic diet, composed essentially according to Nishina et al. (18)
(Hope Farms BV). The LFC diet contained 50.5% sucrose, 12.2%
corn starch, 5% corn oil, and 5% cellulose, by weight, and was fed to
the mice for a period of 3 wk.
Male apo E–deficient and control mice were used for cell isola-
tions. These mice were fed a normal chow diet (RMH-B; Hope Farms




 0.01% cholesterol by weight.
Experimental protocols were approved by the Ethics Committee
for Animal Experiments of the University of Groningen.
 
Serum lipid and lipoprotein analysis.
 
Levels of total plasma cho-
lesterol and TG were measured, with or without free glycerol, using
commercially available enzymatic kits (236691 and 701904; Boeh-
ringer Mannheim GmbH, Mannheim, Germany, and 337-B; Sigma
Chemical Co., St. Louis, MO, respectively). The phospholipid con-
tent of nascent VLDL particles secreted from the perfused mouse
liver was determined using an analytical kit (Wako Chemicals
GmbH., Neuss, Germany). Total cholesterol and free cholesterol
contents in nascent VLDL fractions were measured fluorometrically




7.4) using cholesterol oxidase and peroxidase (Boehringer Mannheim
GmbH), 0.5% Triton X-100 (Merck, Darmstadt, Germany), 20 mM
cholic acid, and 4 mg/dl para-hydroxy-phenyl-acetic acid (Sigma
Chemical Co.). Before measurements, total cholesterol was extracted
using KOH/ethanol/hexane, and free cholesterol using ethanol/hex-
ane. Esterified cholesterol was calculated as the difference between
total and unesterified cholesterol.
Protein concentrations in VLDL fractions were measured accord-
ing to Lowry et al. (19) using BSA (Sigma Chemical Co.) as standard.
 
In vivo hepatic VLDL-TG production using Triton WR1339.
 
Un-
treated and bone marrow–transplanted mice were injected intrave-
nously with 500 mg of Triton WR1339 (Sigma Chemical Co.) per kg
body wt as a 15-g/dl solution in 0.9% NaCl after an overnight fast.
Previous studies have shown that plasma VLDL clearance is virtually





l) were taken at 0, 1, 2, 3, and 4 h after Triton WR1339 injection,
and plasma TG was measured enzymatically as described above.
Plasma TG concentrations were related to the body mass of the ani-
mals, and the hepatic TG production rate was calculated from the





Experiments were always begun be-
tween 10 and 11 a.m. Fed mice were anesthetized by intraperitoneal
injection of 0.5 ml/kg Hypnorm (Janssen-Cilag Pharmaceutica BV,
Tilburg, The Netherlands) and 12.5 mg/kg midazolam (Roche Neth-
erlands BV, Mijdrecht, The Netherlands). After cannulation of the




 19 mm; Abbott
Laboratories, Kent, UK), livers were isolated and perfused (1.5 ml/





C throughout the experiment. The recirculating perfu-
sate (20–30 ml) was an RPMI buffer (RPMI 1640 medium; ICN Bio-
medicals, Inc., Costa Mesa, CA), pH 7.5, containing 1 mM vitamin C,
5 mM glutathione, and 2.5% (wt/wt) BSA. Oleate was added as a
BSA-complex to the perfusate to reach a concentration of 1 mM in all









perfused livers were functionally viable by gross appearance after a 3-h
perfusion period. At termination of the experiment, livers were per-
fused with blue dye (Polysciences Inc., Warington, PA) to assess
grade of perfusion, cleansed of all extrahepatic nonperfused tissue,
and weighed.
Before isolation of nascent VLDL, the 20–30 ml of perfusate was
concentrated to 10 ml (Centriprep 30; Amicon, Inc., Danvers, MA).








 1.006 g/ml) were isolated by ultracen-
trifugation at 40,000 rpm in a swingout rotor (model SW-40; Beck-










C. The lipid composition of the nascent VLDL particles
was analyzed as described above.
 
Preparation and culture of mouse hepatocytes.
 
Hepatocytes were
isolated from mouse livers as described previously by Klaunig et al.
(21). Briefly, the portal vein was cannulated with a 22-gauge plastic
cannula. First, the liver was perfused with calcium-free HBSS con-









, and adjusted to pH 7.42, at a flow rate of 4 ml/min. Sub-
sequently, the liver was perfused with a collagenase solution (20 mg





 10–15 min until swelling of the liver was observed.
Hepatocytes were then gently released from the surrounding capsule.
Isolated hepatocytes were washed three times with Williams’ E me-
dium (Life Technologies Ltd., Paisley, UK) containing 5% (wt/wt)
BSA. Hepatocytes were isolated with similar yields from livers of












cells/liver. The viability of hepatocytes was assessed by trypan blue
(final concentration 0.2%) exclusion immediately after isolation, and
varied between 65 and 80% of the total amount of cells isolated. No
differences were observed in this respect between cells isolated from
apo E–deficient and control mice. Cells were plated in 35-mm 6-well
plastic dishes (Costar Corp., Cambridge, MA), precoated with col-
lagen (Serva Feinbiochemica, Heidelberg, Germany), at a density of
 












 viable cells/well in 2 ml culture medium. After a 2-h adher-
ence period, nonviable cells were removed from the cultures by care-
ful washing. The culture medium consisted of Williams’ E medium




g/ml of penicillin and streptomycin (Life Technologies Ltd.), 4 mU/




g/ml dexamethasone (both from Novo Nordisk
Pharma BV, Amsterdam, The Netherlands) as described previously




C in an atmosphere




 and rapidly formed monolayers.
The total synthesis and secretion of proteins by cultured hepato-




H]leucine incorporation into TCA-precipi-








Ci/ml per well; Am-
ersham International, Little Chalfont, UK) was added to the medium
3 h before termination of cell incubation. Both the protein synthesis
and the secretion of newly synthesized protein were similar in over-
night cultured hepatocytes isolated from apo E–deficient and control
mice.
Lactate dehydrogenase (LDH) activity in media and cells was de-
termined as reported previously (23). No differences were observed
in LDH leakage from hepatocytes isolated from apo E–deficient or




 95% of the LDH activity was found intra-
cellularly.
 
Experimental protocols for cultured hepatocytes.
 
After an over-
night culture, FCS-containing medium was removed from the wells,
and cells were washed twice with FCS/hormone-free medium. Cells
were incubated subsequently with FCS/hormone-free medium (1 ml/
well, pH 7.4) containing 0.25 mM BSA only, or BSA–oleate complex




C for either 4 or 24 h. In all ex-
periments, oleate was used to stimulate hepatocytic lipogenesis. Me-
dium containing BSA–oleate complexes was freshly prepared on the
day of each experiment.


























l ethanol; Amersham Interna-
tional) was added to each well according to different experimental
protocols (see figure citations in Results). All incubations were per-
formed in triplicate and terminated by placing the culture plates on
ice. Media were collected and centrifuged at 10,000 rpm for 2 min to
remove suspended cells. Cells were washed three times with cold PBS















C]acetate (Amersham International) incorporation into sterols.
Previous studies have indicated that this method yields relative values


















 1.006 g/ml) were isolated from the medium by ultracen-
trifugation at 41,000 rpm in a TST 41.14 rotor (Kontron Instruments,




C. The radiolabeled lipids from VLDL and
cells were extracted with chloroform/methanol (1:2, vol/vol). Before
lipid extractions, cells were first thawed and resuspended by passing




 25 mm) needles five times. Radiolabeled cellu-
lar TG, free cholesterol, cholesterol ester, and phospholipids were
separated by TLC on silica gel 60 plates (Merck) with hexane/diethyl-
ether/acetic acid (80:20:1, vol/vol/vol) as resolving solution. Before
TLC analysis, tripalmitin (Sigma Chemical Co.) in chloroform was
added to each sample as a carrier for TG determination. After iodine
staining of the silica gel plates, the spots containing the lipids of inter-
est were scraped into vials and assayed for radioactivity by scintilla-
tion counting.
In another set of experiments, TG content of VLDL and cells was
measured using a commercially available kit from Boehringer Mann-
heim GmbH as described above. Free cholesterol and cholesterol
ester contents were determined according to the methods developed
by Gamble et al. (25). Phospholipids were determined by measuring





VLDL fractions were prepared for electron
microscopy analysis within 1 h after their isolation by ultracentrifuga-
tion. The particles were allowed to adhere to hydrophilic carbon films
and were immersed in 2% potassium phosphotungstate (pH 7.4) as a
negative stain. Electron micrographs were obtained in a transmission
electron microscope (model EM208; Philips Electron Optics, Eind-
hoven, The Netherlands). Size distribution of VLDL particles was de-




 software (Leica Cambridge Ltd.,
Cambridge, UK).
 
Western blotting of apo B.
 
VLDL particles were isolated from
the media by ultracentrifugation as described above and adsorbed to





Sigma Chemical Co.) as reported previously (27). The VLDL apo B
and apo E contents were analyzed by immunoblotting as described by
Lin et al. (28) using rabbit anti–rat apo B serum showing cross-reac-
tivity with murine apo B (a kind gift of Roger A. Davis, San Diego
State University, San Diego, CA) and rabbit anti–mouse apo E serum
(kindly provided by Pieter H.E. Groot, SmithKline Beecham Phar-




In vivo VLDL-TG production rate in apo E–deficient mice: effect
of bone marrow transplantation.
 
The effect of apo E defi-
ciency on the in vivo VLDL-TG production rate was deter-
mined by injecting apo E–deficient and control mice with Triton
WR1339. Table I shows that the hepatic TG production rate













mol TG/h/kg, respectively). To ver-
ify whether this effect is attributable to the lack of apo E
within the hepatocytes, and not to aspecific changes in liver
function due to the hypercholesterolemia associated with apo
E deficiency, wild-type mouse bone marrow cells expressing
apo E were transplanted into apo E–deficient mice. In these
mice, bone marrow–derived macrophages are the only sources
of apo E, i.e., there is no expression of apo E in hepatocytes.
 
Table I. Plasma Lipid Levels and In Vivo VLDL-TG 
Production Rates in apo E–deficient and Control Mice: Effects 






































































) and TG levels were measured in the plasma of
fasted apo E–deficient and control (C57BL/6J) mice using enzymatic
kits (236691 and 701904, respectively; Boehringer Mannheim). Irradi-










) was measured by injecting mice with Triton
WR1339 (500 mg/kg). For the transplanted mice, Triton WR1339 was
injected 16–20 wk after bone marrow transplantation. Plasma TG levels
were determined before injection (0 min) and at 30, 60, 120, 180, and
240 min after Triton injection. Hepatic VLDL-TG production rate was








 0.05, indicating significant
differences between untreated control and apo E–deficient mice, or be-










Bone marrow transplantation effectively reversed hypercho-
lesterolemia in apo E–deficient mice (Table I), as reported
previously by other groups (29, 30). Introduction of wild-type
bone marrow into control mice had no effect on plasma lipid
concentrations (Table I). In spite of normalized plasma lipid
levels, VLDL-TG production rates remained inhibited in
transplanted apo E–deficient mice compared with the trans-













respectively) (Table I). These results indicate that the reduced
hepatic TG production observed in apo E–deficient mice is re-
lated to the absence of apo E in the liver.
 
Secretion of nascent VLDL by isolated perfused mouse liv-
ers.
 
To investigate the effects of apo E deficiency on nascent
VLDL-TG production by polarized hepatocytes in their physi-
ological environment, we performed studies with isolated per-
fused livers from apo E–deficient and control mice. To stimulate
VLDL-TG production (18), mice were fed the sucrose-con-
taining LFC diet for a period of 3 wk before the liver perfusion
experiments.
VLDL-TG secretion by isolated perfused mouse livers was
linear during a 3-h period of perfusion (data not shown), indi-
cating that the liver remains functionally viable during this
time period. VLDL-TG production by perfused livers from
apo E–deficient mice was reduced by 50% compared with per-
fused control livers (Table II). In addition, the nascent VLDL
particles produced by apo E–deficient livers had a lipid com-
position similar to nascent VLDL secreted by control livers
(Table II).
 
Characteristics of nascent VLDL particles produced by
mouse hepatocytes in primary culture.
 
The TG and cholesterol
contents of apo E–deficient cells cultured for 24 h in the ab-
sence of oleate (0.75 mM) were elevated significantly com-
pared with control cells, whereas no differences in cholesterol
ester and phospholipid content were found (Table III). The
presence of oleate in the incubation medium resulted in a
marked TG accumulation in both apo E–deficient and control
cells compared with oleate-free conditions (Table III).
The secretion of nascent VLDL by cultured hepatocytes





g/ml fractions obtained by density gradient ultracentrifugation





), apo E–deficient cells produce slightly but significantly
less VLDL-TG compared with control cells in the absence of
oleate (77% of control values). The total mass lipid secretion









 in Fig. 1). In contrast, VLDL-TG pro-
duction by apo E–deficient cells was strongly reduced in the





thermore, the relative lipid composition of VLDL secreted by
apo E–deficient and control cells appeared to be similar under
all conditions (Fig. 1).
Western blot analysis revealed that apo B48 is the major
form of apo B secreted by control and apo E–deficient mouse
hepatocytes, which is consistent with the high level of apo B
mRNA editing activity in mouse liver (31) (results not shown).
As expected, apo E could be detected in VLDL particles pro-
duced by control cells but not in those from apo E–deficient
cells (data not shown).





fractions was determined by electron microscopy. As shown




), no differences in size were found between apo
E–deficient and control particles when cells were cultured un-









tively). In contrast, when cells were cultured in the presence of
oleate, the average diameter of apo E–deficient VLDL parti-













). The average size of
VLDL particles formed in the presence of oleate was signifi-







right panels in Fig. 2).
Since the size of apo E–deficient VLDL was smaller than
control VLDL under oleate-stimulated conditions, it was in-
vestigated whether these particles could be recovered in higher
density fractions upon ultracentrifugation. Therefore, we per-
formed cell incubation experiments in the presence of 0.75
mM oleate and [3H]glycerol to label the newly synthesized lip-
ids. After 24 h of incubation, the medium was harvested, and
VLDL was isolated by ultracentrifugation. Although the total
amount of radiolabeled lipids secreted by apo E–deficient cells
is decreased compared with control cells, most of the radioac-
Table II. VLDL-TG Production Rate and Relative Lipid 
Composition of Nascent VLDL Secreted by Perfused Livers 
from apo E–deficient and Control Mice
Nascent VLDL
VLDL-TG
production TG FC CE PL
mg TG/g liver % of total lipid (by wt)
Control 317646 8064 261 561 1364
apo E–deficient 158623* 7566 261 965 1765
Livers of female apo E–deficient and control (C57BL/6J) mice fed a su-
crose-based semisynthetic (LFC) diet for 3 wk were perfused in a recir-
culating fashion as described in Methods. After 3 h of liver perfusion,
perfusates were collected, and nascent VLDL was isolated by ultracen-
trifugation and analyzed for its lipid composition. TG, free cholesterol
(FC), cholesterol ester (CE), and phospholipid (PL) contents of nascent
VLDL particles were determined as described in Methods. Values are
given as mean6SD of four individual liver perfusion experiments per
group. *P , 0.05, indicating a significant difference between apo E–defi-
cient and control perfused liver preparations, using Student’s t test.
Table III. Cellular Lipid Content of apo E–deficient and 
Control Mouse Hepatocytes in Primary Culture
TG FC CE PL
nmol/mg protein
No oleate Control 8169 3463 461 206625
apo E–deficient 142650* 5868* 561 251644
With oleate Control 277679‡ 3966 662 255652
apo E–deficient 304671‡ 5164* 962 286646
Cells were cultured for 24 h in the absence or presence of oleate (0.75
mM) and were subsequently washed and harvested for lipid analysis.
Cellular TG, free cholesterol (FC), cholesterol ester (CE), and phos-
pholipid (PL) contents were measured as described in Methods. Val-
ues are expressed as mean6SD of four individual hepatocyte prepara-
tions per group. *P , 0.05, indicating a significant difference between
apo E–deficient and control preparations under the same culture condi-
tions. ‡P , 0.05, indicating a significant difference between hepatocyte
preparations in the absence or presence of oleate, using Student’s t test.
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tivity is recovered from the , 1.006 g/ml fractions for both
control and apo E–deficient cells (Fig. 3). Thus, these results
indicate that the decreased recovery of apo E–deficient VLDL
in the , 1.006 g/ml fraction is due to an impaired VLDL secre-
tion by apo E–deficient hepatocytes, rather than to a shift in
the density of apo E–deficient particles.
Secretion of newly synthesized TG by hepatocytes in pri-
mary culture. To compare the cellular synthesis and secretion
of newly formed lipids by control and apo E–deficient cells, we
performed incubation experiments with either [3H]glycerol or
[3H]oleate to label the newly synthesized TG. Fig. 4 shows
a similar time-dependent cellular accumulation of [3H]TG
formed from radiolabeled glycerol in apo E–deficient and
wild-type cells, both in the absence (Fig. 4 A) and presence
(Fig. 4 B) of oleate. Similar results were obtained in three ad-
ditional independent experiments in which [3H]TG production
by apo E–deficient and control cells was compared. On aver-
age, the cellular [3H]TG content was 30% (without oleate) and
24% (with oleate) higher in apo E–deficient than in control
hepatocytes, after 3 h of incubation. However, these differ-
ences were not statistically significant. In contrast, the [3H]TG
secretion by apo E–deficient cells was decreased significantly,
by 60% in the absence (Fig. 4 C) and 73% in the presence of
oleate (Fig. 4 D) compared with control cells. Similar results
were obtained when [3H]oleate was used to label the newly
synthesized lipids.
Measurement of the incorporation of [14C]acetate into cel-
lular cholesterol, indicative for cholesterol biosynthesis, did
not reveal any significant difference in this respect between
apo E–deficient and control cells, either in the absence or pres-
ence of oleate in the incubation media (data not shown).
Discussion
Production of VLDL by the liver is an important determinant
of plasma lipid levels in humans. It is well-established that apo
B is required for the assembly and secretion of these TG-rich
lipoproteins by liver cells, and that each particle contains a sin-
gle apo B molecule (32). Although controversies still exist,
most of the available data, as summarized in recent reviews
(33–36), indicate that regulation of apo B secretion is primarily
a posttranslational event governed by the efficiency of translo-
cation of the protein across the endoplasmic reticulum mem-
brane and its association with lipids. Excess of apo B that does
not associate appropriately with lipids inside the endoplasmic
reticulum lumen is degraded rapidly. There is a large body of
experimental evidence indicating that both the availability of
core (TG, cholesterol ester) and surface lipid (phospholipid)
can become rate-limiting for VLDL production. Furthermore,
several studies have shown that the microsomal triglyceride
transfer protein is essential for adequate lipoprotein formation
(37–39). In addition, other proteins have been identified that
Figure 1. VLDL-associated lipid secretion 
by apo E–deficient and control mouse 
hepatocytes. Cells were cultured for 24 h in 
the absence (left panel) or presence (right 
panel) of 0.75 mM oleate as described in 
Methods. Lipoproteins were isolated from 
the , 1,006 g/ml fraction after density gra-
dient ultracentrifugation of medium sam-
ples, and lipid composition was analyzed, 
as described in Methods. Values are ex-
pressed as mean6SD of four independent 
experiments in each group. *P , 0.05, indi-
cating significant differences between apo 
E–deficient (black bars) and control cells 
(white bars) under the same culture condi-
tions. 'P , 0.05, indicating significant differences between absence and presence of oleate, using Student’s t test. CH, Cholesterol. CHE, Choles-
terol ester. PL, phospholipid.
Figure 2. Frequency distribution of particle 
diameter of VLDL produced by apo
E–deficient and control mouse hepatocytes. 
apo E–deficient (black bars) and control 
(C57BL/6J) mouse (white bars) hepato-
cytes were cultured for 24 h in the absence 
(left panel) or presence (right panel) of 0.75 
mM oleate, as described in Methods. Lipo-
proteins (d , 1.006 g/ml) were isolated 
from the media by ultracentrifugation and 
studied by electron microscopy, as de-
scribed in Methods. Values are expressed 
as the mean of four independent VLDL 
preparations per group. SD bars are not 
shown for clarity reasons. In each prepara-
tion, z 500 particles were analyzed.
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may play a role in the assembly of VLDL (for a review, see ref-
erence 35).
In this study, data are presented that identify apo E as an
additional factor involved in the regulation of VLDL assembly
and secretion by hepatocytes. A pronounced reduction in
VLDL-TG secretion by apo E–deficient liver cells was ob-
served in three different experimental systems, i.e., in the intact
animal, in the isolated perfused liver, and in hepatocytes in pri-
mary culture. It could be argued that the decreased VLDL-TG
secretion by apo E–deficient hepatocytes is not directly related
to the lack of apo E, but rather to aspecific changes in the liv-
ers of apo E–deficient mice as induced by profound hypercho-
lesterolemia. To address this possibility, in vivo hepatic TG
production studies were performed with apo E–deficient mice
in which the hypercholesterolemia was effectively reversed
by transplantation of wild-type bone marrow. These studies
showed that hepatic TG production is still severely impaired in
bone marrow–transplanted apo E–deficient mice (Table I). In
addition, no differences were observed between cultured apo
E–deficient and control hepatocytes with respect to cell viabil-
ity, protein synthesis and secretion, and LDH leakage. Alto-
gether, these data indicate strongly that the reduced TG secre-
tion by apo E–deficient liver cells is caused primarily by the
absence of apo E.
To gain more insight into the mechanisms underlying re-
duced TG secretion by apo E–deficient liver cells, nascent
VLDL-TG secretion studies were performed using isolated
perfused mouse livers and cultured hepatocytes. One of the
major advantages of the perfused liver model is that the hepa-
tocytes maintain their secretory polarity, a feature that is obvi-
ously lost in cell culture. Secretion of VLDL-TG by livers from
apo E–deficient mice was reduced by 50% compared with con-
trol mice. In addition, perfused mouse livers of either strain
produced nascent VLDL particles with similar lipid composi-
tion (Table II), indicating that apo E–deficient mouse livers es-
sentially produce normal TG-rich VLDL.
Much of our knowledge of the VLDL production process is
derived from in vitro studies with hepatoma cell lines and pri-
mary hepatocyte cultures. Human (HepG2) and rat (McA-
RH7777) hepatoma cell lines (15, 16) as well as SV40 large T
antigen–immortalized human hepatocytes (40) typically se-
crete apo B–containing particles in the LDL-density range,
probably as a consequence of their dedifferentiated state, in
which a number of liver-specific functions are lost (40). In con-
trast, short-term primary cultures of rat (41), human (28), and
Figure 3. Density gradient ultracentrifugation profiles of radiola-
beled lipids accumulated in the culture medium of primary hepato-
cytes isolated from control (open symbols) and apo E–deficient 
(closed symbols) mice. Hepatocytes were incubated in serum-free 
media containing [3H]glycerol and 0.75 mM oleate complexed with 
BSA (0.25 mM) for 24 h. After incubation, the media were collected, 
centrifugated to remove any cell debris, and dialyzed extensively. Im-
mediately before ultracentrifugation, 0.5 ml of normal human plasma 
was added as a carrier. Fractions were collected, extracted, and as-
sayed for radioactivity as described in Methods. The data represent 
the mean of three independent experiments per group. Solid line, Av-
erage density of the collected fractions. dps, Desintegrations per 
second.
Figure 4. Time-dependent accumulation of 
[3H]TG in apo E–deficient and control 
hepatocytes and secretion of [3H]TG-
VLDL by these cells. After their isolation, 
apo E–deficient (solid line) and control 
(C57BL/6J) hepatocytes (dotted line) were 
cultured overnight in FCS and hormone-
containing media. Cells were washed thor-
oughly and incubated for an additional 4 h 
in FCS and hormone-free medium. Subse-
quently, cells were incubated with medium 
containing BSA in the absence (A and C) 
or presence (B and D) of 0.75 mM oleate. 
[3H]Glycerol was added to label newly syn-
thesized TG, as outlined in Methods. At the 
indicated time points, cells and media were 
harvested, and the accumulation of cellular 
[3H]TG (A and B) and secretion of [3H]TG-
VLDL (C and D) were determined as de-
scribed in Methods. A representative ex-
periment is shown in which cells isolated 
from a single apo E–deficient mouse and a 
control mouse were studied simultaneously. 
Values are expressed as the mean6SD of 
triplicate determinations at each time point.
Role of Apolipoprotein E in Very Low Density Lipoprotein Production 2921
murine (20) hepatocytes secrete primarily VLDL, reflecting
more closely the in vivo situation. The data depicted in Fig. 3
demonstrate that apo E–deficient hepatocytes in primary cul-
ture secrete newly synthesized lipids primarily in particles of
the VLDL-density range, similar to the situation observed for
wild-type control cells.
Experiments with apo E–deficient hepatocytes in culture
showed an impaired VLDL-TG secretion, both when mass se-
cretion was determined over a 24-h period (Fig. 1) and when
secretion of newly synthesized TG from radiolabeled precur-
sors was measured (Fig. 4, C and D). This impaired VLDL-TG
secretion by apo E–deficient hepatocytes was not likely to be
caused by decreased intracellular TG synthesis, since the TG
synthesis rate as measured by [3H]glycerol incorporation was
similar for apo E–deficient and control cells (Fig. 4, A and B).
In addition, apo E–deficient cells showed significantly higher
TG and cholesterol contents compared with cells from wild-
type mice (Table III). This is consistent with our previous in
vivo observations (17), although the difference in hepatic TG
content was larger under in vivo conditions. This may be due
to selective isolation of relatively lipid-poor cells from peripor-
tal areas (zone 1), since it was found that TG-containing fat
droplets are localized predominantly in perivenous (zone 3)
hepatocytes in apo E–deficient livers (17). Alternatively, the
lipid-laden zone 3 cells may have been lost more easily during
isolation and subsequent washing procedures.
In the absence of oleate, cells from apo E–deficient mice
secreted less VLDL-TG, whereas the VLDL particles were of
similar size and composition as those secreted by cells from
control mice (Figs. 1 and 2). These data point to a significant
reduction in the number of VLDL particles secreted by apo
E–deficient hepatocytes. Since each VLDL particle contains a
single molecule of apo B, secretion of this apolipoprotein must
also be reduced. However, in the presence of oleate, VLDL
particles formed by apo E–deficient cells were significantly
smaller than those produced by control cells (Fig. 2). A simple
calculation shows that the 10.7-nm difference in diameter be-
tween apo E–deficient and control particle size (Fig. 2) results
in a 2.2-fold larger particle volume for VLDL produced by
control cells. This value relates reasonably well to the 2.6-fold
higher production of core lipids by control cells under these
conditions (Fig. 1). Thus, under oleate-stimulated conditions,
it is suggested that apo E–deficient hepatocytes secrete smaller
VLDL particles, but their overall number is not affected.
Clearly, further studies are necessary to establish the modulat-
ing effect of apo E on VLDL particle size and secretion. Such
experiments, including detailed analysis of apo B synthesis and
secretion, are currently being performed in our laboratory.
Previous studies have shown that the synthesis rate of cho-
lesterol in the liver may affect VLDL secretion (42). In this
study, the incorporation of [14C]acetate into cellular choles-
terol was similar in control and apo E–deficient cells both in
the absence and presence of oleate in the incubation medium.
These results indicate that the impaired VLDL production by
apo E–deficient hepatocytes observed in this study is not
caused by differences in cholesterol biosynthesis.
How does apo E influence VLDL particle assembly and se-
cretion? As outlined in the Introduction, Fazio et al. (15) have
reported an enhanced association of apo E with large, apo
B–containing lipoproteins during stimulation of lipogenesis in
HepG2 cells, while the total amount of apo E secretion did not
change. Similar findings were also reported in a study by Davis
et al. (43) using rat hepatocytes in primary culture. Fazio and
Yao (16) speculated that this increased association reflects a
physical preference of apo E for the larger particles, providing
an effective way to enrich these particles with apo E in order to
facilitate subsequent carrier-mediated uptake of their rem-
nants from blood. However, our data strongly suggest that apo
E actually has a function in the assembly–secretion process at
the intracellular level, in particular when lipogenesis is stimu-
lated by the presence of oleate in the culture media. Although
the exact mechanism(s) remains to be elucidated, our data
seem to indicate that apo E is involved in the incorporation of
(newly synthesized) TG into VLDL particles produced by
mouse liver cells. At this point, it is tempting to speculate that
apo E interferes with the recruitment of newly synthesized TG
into the small microsomal secretion-coupled pool of TG that is
suggested to be involved in the regulation of apo B secretion
(44). Interestingly, Gretch et al. (45) have found recently that
the expression of human apo E in insect larvae leads to pro-
gressive conversion of the endogenous lipoproteins into more
buoyant species. Although there clearly are major differences
in lipoprotein assembly between the insect and mammalian
systems, this finding demonstrates that apo E can influence the
amount of lipid assembled into lipoproteins and thereby affect
their size and buoyant density. Thus, in conclusion, we propose
that in addition to its well-established function in lipoprotein
uptake by the liver, apo E also plays an important physiologi-
cal role in lipoprotein formation by hepatocytes.
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